Biogen
-
Biogen trims Apellis pipeline programs months after US$5.6B acquisition
Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.
-
Biogen expands immunology footprint with US$1B acquisition of RayThera
Under the agreement, Biogen will integrate RayThera’s portfolio of anti-inflammatory and immune-modulating candidates into its broader research and development engine.
-
Biogen secures FDA breakthrough status for once-yearly spinal muscular atrophy drug Salanersen
The regulatory decision follows results from a Phase Ib study presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference and the 2026 International Scientific Congress on SMA Europe.
-
Biogen secures global rights to felzartamab in US850M deal with TJ Biopharma
Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.
-
Biogen acquires Apellis Pharmaceuticals for USD5.6B to fuel immunology growth
The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.
-
Biogen completes USD85M acquisition of Alcyone Therapeutics to advance CNS drug delivery technology
The acquisition centers on Alcyone’s innovative ThecaFlex DRx drug delivery system, an experimental implantable device that represents a significant advancement in treating neurological disorders.